ticlopidine has been researched along with nifedipine in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (10.00) | 18.7374 |
1990's | 4 (20.00) | 18.2507 |
2000's | 2 (10.00) | 29.6817 |
2010's | 12 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cillero, FJ; Fau de Casa-Juana, M; Ortega, MP; Priego, JG; Sunkel, CE | 1 |
Fujita, M; Iso, T; Iwao, J; Kato, E; Kawashima, Y; Oya, M; Tabashi, K; Yamamoto, K | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Budriesi, R; Carosati, E; Chiarini, A; Chiu, FC; Cosimelli, B; Frosini, M; Fusi, F; Ioan, P; Katneni, K; Matucci, R; Micucci, M; Saponara, S; Severi, E; Spinelli, D | 1 |
Fernández-Sanz, S; Gago Angelino, J; Hevia Alonso, A; López-Valpuesta, FJ; Serrano Molina, JS | 1 |
Borgia, MC; Calpicchio, A; De Paola, G; Di Folco, G | 1 |
Ishii, A; Karasawa, A; Kawakage, M; Kubo, K; Miki, I; Shirakura, S; Takeda, M | 1 |
Dickinson, JP; Forbes, CD; Kieffer, G; Lowe, GD; MacLaren, M; Shaw, BG | 1 |
Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H | 1 |
1 review(s) available for ticlopidine and nifedipine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for ticlopidine and nifedipine
Article | Year |
---|---|
[The effects of ticlopidine and nifedipine on platelet aggregation in patients with obliterating arteriopathy of the lower limbs].
Topics: Arteriosclerosis Obliterans; Clinical Trials as Topic; Female; Humans; Leg; Male; Middle Aged; Nifedipine; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 1992 |
Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Arterial Occlusive Diseases; Atenolol; Calcium Channel Blockers; Clopidogrel; Coronary Disease; Cross-Over Studies; Double-Blind Method; Drug Incompatibility; Female; Humans; Male; Middle Aged; Nifedipine; Platelet Aggregation Inhibitors; Ticlopidine | 1999 |
17 other study(ies) available for ticlopidine and nifedipine
Article | Year |
---|---|
Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines.
Topics: Animals; Cats; Collagen; Dihydropyridines; Humans; Kinetics; Male; Mice; Nitrendipine; Platelet Aggregation; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Thrombosis | 1988 |
Novel calcium antagonists. Synthesis and structure-activity relationship studies of benzothiazoline derivatives.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Guinea Pigs; Heart Conduction System; In Vitro Techniques; Male; Mice; Muscle Contraction; Muscle, Smooth; Pulmonary Embolism; Rabbits; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Thiazoles | 1988 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.
Topics: Animals; Cells, Cultured; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Guinea Pigs; Heart Atria; Humans; Male; Microsomes, Liver; Myocytes, Cardiac; Oxadiazoles; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazines; Vasodilator Agents | 2016 |
[Nifedipine and gingival hypertrophy].
Topics: Angina Pectoris; Drug Therapy, Combination; Gingival Hypertrophy; Humans; Male; Middle Aged; Nifedipine; Oxprenolol; Ticlopidine; Time Factors | 1991 |
Beneficial effect of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate on collagen-induced coronary ischemia in guinea-pigs.
Topics: Animals; Arrhythmias, Cardiac; Benzimidazoles; Benzoxepins; Collagen; Coronary Disease; Cyclooxygenase Inhibitors; Electrocardiography; Guinea Pigs; Heart Arrest; Male; Nifedipine; Phenylacetates; Propranolol; Sulfonamides; Thromboxane A2; Thromboxane B2; Thromboxanes; Ticlopidine | 1991 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent Claudication; Male; Nifedipine; Platelet Aggregation; Rats; Rats, Wistar; Skin; Spinal Cord; Tetrazoles; Ticlopidine; Time Factors; Walking | 2003 |